Dementias 2026 Programme
Dementias 2026 was a two-day conference highlighting the key challenges, advances and best practice in the world of dementia care.
Curated by conference chairs John O'Brien and Alistair Burns, the Dementias 2026 programme consisted of specialist-led talks on:
This event has previously been sponsored by Eisai, Join dementia research, Lilly, Roche, Alzheimer's Research UK, GE Healthcare and Lantheus through a financial contribution towards the congress, but they have had no input into the content. The content is intended for UK healthcare professionals (HCPs) and other relevant decision-makers (ORDMs) only, not the public.
Sebastion Walsh, Dept Public Health, University of Cambridge
Mia Kivipelto, Professor, Imperial College London
In this talk, Mia Kivipelto, will explore the potential for dementia prevention and the evidence for wh
Timothy Rittman, Senior Clinical Research Associate, University of Cambridge
Matthew Jones, Consultant Neurologist, Manchester Centre for Clinical Neurosciences
This talk will be clinically focused and will provide an overview of some of the more uncommon dementias we all encounter from time to time. The talk will focus on recognising the main clinical patterns and provide hints and tips on making the most accurate diagnosis possible.
Sponsored by:
Vanessa Raymont, Associate Professor, University of Oxford and Dementias Platform UK
This talk will cover the current status of blood biomarkers for both research and clinical use for the diagnosis and prognosis of causes of dementia, and where future opportunities and challenges may lie for clinical service use.
Ming Hung Hsu, Professor of Music Therapy, Norwegian Academy of Music
This session is built on lived experiences.
Sponsored by:
Jeremy Isaacs, National Clinical Director for Dementia, NHS England
Abstract:
Over 500,000 people are now living with a formal dementia diagnosis in England, a number projected to increase significantly due to demographic ageing. The NHS has made notable progress in diagnosis, public awareness, and the development of dementia-friendly services. Memory services are busier than ever, seeing 200,000 new patients per year, while a diverse community of voluntary sector providers offer a range of post-diagnostic support options.
However, significant challenges remain. Waiting times in memory services are increasing; over 50% of patients are now waiting over 18 weeks from referral to diagnosis. The quality of diagnosis is inconsistent, with significant variations in subtype diagnosis. Delirium remains under-recognised and recorded.
Too many people living with dementia as patients or carers feel unsupported after a diagnosis. Addressing these challenges requires efficient resource use, targeted investment in cost-effective diagnostics and interventions, enhanced workforce training, better use of data, greater integration between health providers, leveraging the emerging neighbourhood health model to implement consistent post-diagnostic support and a public health approach to dementia risk reduction. The Frailty & Dementia Modern Service Framework presents a generational opportunity to ensure equitable access to high-quality dementia care across England.
Ross Dunne, Consultant Later Life Psychiatrist, Greater Manchester Mental Health Trust (GMMH)
Ross Dunne will present the cases of three (anonymised) people with varying complexities at the Manchester Brain Health Centre, a clinic focused on timely diagnosis and risk reduction.
Jeremy Isaacs, National Clinical Director for Dementia and Older People's Mental Health, NHS England
Abstract:
Over 500,000 people are now living with a formal dementia diagnosis in England, a number projected to increase significantly due to demographic ageing. The NHS has made notable progress in diagnosis, public awareness, and the development of dementia-friendly services. Memory services are busier than ever, seeing 200,000 new patients per year, while a diverse community of voluntary sector providers offer a range of post-diagnostic support options.
However, significant challenges remain. Waiting times in memory services are increasing; over 50% of patients are now waiting over 18 weeks from referral to diagnosis. The quality of diagnosis is inconsistent, with significant variations in subtype diagnosis. Delirium remains under-recognised and recorded.
Too many people living with dementia as patients or carers feel unsupported after a diagnosis.
Addressing these challenges requires efficient resource use, targeted investment in cost-effective diagnostics and interventions, enhanced workforce training, better use of data, greater integration between health providers, leveraging the emerging neighbourhood health model to implement consistent post-diagnostic support and a public health approach to dementia risk reduction. The Frailty & Dementia Modern Service Framework presents a generational opportunity to ensure equitable access to high-quality dementia care across England.
Professor Dame Louise Robinson, Regius Professor of Ageing, Newcastle University
This talk will examine the role of primary care in providing dementia care and support and the evidence base underpinning primary care dementia service provision.
James Rowe, Dept of Clinical Neurosciences at University of Cambridge
This talk will cover recent developments in understanding of fronto-temporal dementia
Dennis Chan, Professorial Research Fellow, Institute of Cognitive Neuroscience, University College London
This talk will cover new criteria for diagnosing and staging Alzheimer’s disease, including the role of biomarkers in diagnosis, the use of blood biomarkers in routine clinical practice, and a comparison of the 2024 Alzheimer’s Association and International Working Group diagnostic guidelines. It will also explore preclinical and clinical staging of the condition.
Judith Harrison, NIHR Academic Clinical Lecturer, Newcastle University
ENTER AN ABSTRACT ON THE USE OF AI TALK
Annabel Price
1. A Legal Perspective
Alex Ruck Keene, Barrister, Professor of Practice, 39 Essex Chambers & King's College London
Alex Ruck Keene will set out how to reduce unnecessary complexity in capacity assessment, address necessary complexity, and document conclusions about capacity in a legally defensible fashion.
2. A Clinical Perspective
James Warner, Honorary Clinical Senior Lecturer, Faculty of Medicine Centre, Imperial College
John-Paul Taylor, Newcastle University
The approach to genetics has changed dramatically over the past few years. This talk will review when to test for genetics forms of dementia, and provide an overview of the testing process. The aim is to help identify people with dementia to whom you would offer a genetic test and to create confidence in interpreting and discussing the results.
CATHERINE CAN'T ATTEND
Professor Catherine Mummery, Professor of Neurology; Director NIHR UK Dementia Trials Network; Head of Clinical Trials, Dementia Research Centre
